Natural antimicrobial peptides against Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1285-1289

  Abedinzadeh, Maria ^a   Gaeini, Mahdieh ^a   Sardari, Soroush ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Antimycobacterial agents; Drug resistant tuberculosis; TB; Toxicity; Tuberculosis

Indexed keywords

NATURAL PRODUCT; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BIOLOGICAL PRODUCT; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; PLANT;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTITUBERCULAR AGENTS; BIOLOGICAL PRODUCTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PLANTS;

EID: 84929761144     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku570     Document Type: Article

References (54)

1. Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine 2007; 25:3742-51.
2. Garcia A, Bocanegra-Garcia V, Palma-Nicolas JP et al. Recent advances in antitubercular natural products. Eur J Med Chem 2012; 49:1-23.
3. Kapoor R, Eimerman PR, Hardy JW et al. Efficacy of antimicrobial peptoids against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55:3058-62.
4. WHO. Global Tuberculosis Control Report. WHO/HTM/TB/2013.15. http:// www.who.int/tb/publications/global_report/gtbr13_executive_summary. pdf?ua=1.
5. Zhang Y, Post-Martens K, Denkin S. New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discov Today 2006; 11:21-7.
6. Van den Boogaard J, Kibiki GS, Kisanga ER et al. Newdrugs against tuberculosis:problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009; 53:849-62.
7. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13:1320-30.
8. Maroti G, Kereszt A, Kondorosi E et al. Natural roles of antimicrobial peptides in microbes, plants and animals. Res Microbiol 2011; 162:363-74.
9. Craik DJ, Fairlie DP, Liras S et al. The future of peptide-based drugs. Chem Biol Drug Des 2013; 81:136-47.
10. Schmitt EK, Riwanto M, Sambandamurthy V et al. The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease. Angew Chem Int Ed Engl 2011; 50:5889-91.
11. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55:27-55.
12. Jirakkakul J, Punya J, Pongpattanakitshote S et al. Identification of the nonribosomal peptide synthetase gene responsible for bassianolide synthesis in wood-decaying fungus Xylaria sp. BCC1067. Microbiology 2008; 154:995-1006.
13. Isaka M, Yangchum A, Sappan M et al. Cyclohexadepsipeptides from Acremonium sp. BCC 28424. Tetrahedron 2011; 67:7929-35.
14. Montaser R, Paul VJ, Luesch H. Pitipeptolides C-F, antimycobacterial cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula from Guam. Phytochemistry 2011; 72:2068-74.
15. Giuliani A, Pirri G, Nicoletto S. Antimicrobial peptides: an overview of a promising class of therapeutics. Cent Eur J Biol 2007; 2:1-33.
16. Fjell CD, Hiss JA, Hancock RE et al. Designing antimicrobial peptides:form follows function. Nat Rev Drug Discov 2012; 11:37-51.
17. Seo MD, Won HS, Kim JH et al. Antimicrobial peptides for therapeutic applications: a review. Molecules 2012; 17: 12276-86.
18. Mendez-Samperio P. Role of antimicrobial peptides in host defense against mycobacterial infections. Peptides 2008; 29:1836-41.
19. Rugutt JK, Rugutt KJ. Antimycobacterial activity of steroids, long-chain alcohols and lytic peptides. Nat Prod Res 2012; 26:1004-11.
20. Kalita A, Verma I, Khuller GK. Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J Infect Dis 2004; 190:1476-80.
21. Takayama K, Wang C, Besra GS. Pathway to synthesis and processing ofmycolic acids in Mycobacterium tuberculosis. Clin Microbiol Rev 2005; 18:81-101.
22. Hu J, Miller MJ. Total synthesis of a mycobactin S, a siderophore and growth promoter of Mycobacterium smegmatis, and determination of its growth inhibitory activity against Mycobacterium tuberculosis. J Am Chem Soc 1997; 119:3462-8.
23. Linde CM, Hoffner SE, Refai E et al. In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 2001; 47:575-80.
24. Carroll J, Draper LA, O'Connor PM et al. Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria. Int J Antimicrob Agents 2010; 36:132-6.
25. Li YB, Xie YY, Du NN et al. Synthesis and in vitro antitubercular evaluation of novel sansanmycin derivatives. Bioorg Med Chem Lett 2011; 21:6804-7.
26. Yu SQ, Wang HH, Xie JP et al. In vitro activities of small peptides from snake venom against clinical isolates of drug-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 2003; 22:172-3.
27. Sharma S, Verma I, Khuller GK. Antibacterial activity of human neutrophil peptide 1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur Respir J 2000; 16:112-7.
28. Iwatsuki M, Tomoda H, Uchida R et al. Lariatins, antimycobacterial peptides produced by Rhodococcus sp. K01-B0171, have a lasso structure. J Am Chem Soc 2006; 128:7486-91.
29. Andreu D, Carreno C, Linde Cet al. Identification of an anti-mycobacterial domain in NK-lysin and granulysin. Biochem J 1999; 344:845-9.
30. Linde CM, Grundstrom S, Nordling E et al. Conserved structure and function in the granulysin and NK-lysin peptide family. Infect Immun 2005; 73:6332-9.
31. Gu H, Dai R, Qiu K et al. A synthetic peptide derived from NK-lysin with activity against Mycobacterium tuberculosis and its structure-function relationship. Int J Pept Res Ther 2011; 17:301-6.
32. Yin LM, Edwards MA, Li J et al. Roles of hydrophobicity and charge distribution of cationic antimicrobial peptides in peptide-membrane interactions. J Biol Chem 2012; 287:7738-45.
33. Bourel-Bonnet L, Rao KV, Hamann MT et al. Solid-phase total synthesis of kahalalide A and related analogues. J Med Chem 2005; 48:1330-5.
34. Suksamrarn S, Suwannapoch N, Aunchai N et al. Ziziphine N, O, P and Q, new antiplasmodial cyclopeptide alkaloids from Ziziphus oenoplia var. brunoniana. Tetrahedron 2005; 61:1175-80.
35. Panseeta P, Lomchoey K, Prabpai S et al. Antiplasmodial and antimycobacterial cyclopeptide alkaloids from the root of Ziziphus mauritiana. Phytochemistry 2011; 72:909-15.
36. Ivanova L, Skjerve E, Eriksen GS et al. Cytotoxicity of enniatins A, A1, B, B1, B2 and B3 from Fusarium avenaceum. Toxicon 2006; 47:868-76.
37. Nilanonta C, Isaka M, Chanphen R et al. Unusual enniatins produced by the insect pathogenic fungus Verticillium hemipterigenum: isolation and studies on precursor-directed biosynthesis. Tetrahedron 2003; 59:1015-20.
38. Nilanonta C, Isaka M, Kittakoop P et al. Antimycobacterial and antiplasmodial cyclodepsipeptides from the insect pathogenic fungus Paecilomyces tenuipes BCC 1614. Planta Med 2000; 66:756-8.
39. Luesch H, Pangilinan R, Yoshida WY et al. Pitipeptolides A and B, new cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula. J Nat Prod 2001; 64:304-7.
40. Davis RA, Mangalindan GC, Bojo ZP et al. Microcionamides A and B, bioactive peptides from the philippine sponge Clathria (Thalysias) abietina. J Org Chem 2004; 69:4170-6.
41. Fu LM. The potential of human neutrophil peptides in tuberculosis therapy. Int J Tuberc Lung Dis 2003; 7:1027-32.
42. Shilabin AG, Hamann MT. In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities. Bioorg Med Chem 2011; 19:6628-32.
43. Haritakun R, Sappan M, Suvannakad R et al. An antimycobacterial cyclodepsipeptide from the entomopathogenic fungus Ophiocordyceps communis BCC 16475. J Nat Prod 2010; 73:75-8.
44. Pucci MJ, Bronson JJ, Barrett JF et al. Antimicrobial evaluation of nocathiacins, a thiazole peptide class of antibiotics. Antimicrob Agents Chemother 2004; 48:3697-701.
45. Haneishi T, Nakajima M, Shiraishi A et al. Antimycobacterial activities in vitro and in vivo and pharmacokinetics of dihydromycoplanecin A. Antimicrob Agents Chemother 1988; 32:110-6.
46. Sharma A, Sharma S, Khuller GK et al. In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv. Int J Antimicrob Agents 2009; 34:226-30.
47. Gerard J, Lloyd R, Barsby T et al. Massetolides A-H, antimycobacterial cyclic depsipeptides produced by two pseudomonads isolated from marine habitats. J Nat Prod 1997; 60:223-9.
48. Ashforth EJ, Fu C, Liu X et al. Bioprospecting for antituberculosis leads from microbial metabolites. Nat Prod Rep 2010; 27:1709-19.
49. Huang X, Roemer E, Sattler I et al. Lydiamycins A-D: cyclodepsipetides with antimycobacterial properties. Angew Chem Int Ed Engl 2006; 45:3067-72.
50. Grgurina I, Bensaci M, Pocsfalvi G et al. Novel cyclic lipodepsipeptide from Pseudomonas syringae pv. lachrymans strain 508 and syringopeptin antimicrobial activities. Antimicrob Agents Chemother 2005; 49:5037-45.
51. Isaka M, Palasarn S, Sriklung K et al. Cyclohexadepsipeptides from the insect pathogenic fungus Hirsutella nivea BCC 2594. J Nat Prod 2005; 68:1680-2.
52. Nicolaou KC, Sarlah D, Wu TR et al. Total synthesis of hirsutellone B. Angew Chem Int Ed Engl 2009; 48:6870-4.
53. Vongvanich N, Kittakoop P, Isaka M et al. Hirsutellide A, a new antimycobacterial cyclohexadepsipeptide from the entomopathogenic fungus Hirsutella kobayasii. J Nat Prod 2002; 65:1346-8.
54. Copp BR. Antimycobacterial natural products. Nat Prod Rep 2003; 20:535-57.